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colleen.nelson@qut.edu.auAbstractChitinase 3-like 1 (CHI3L1 or YKL40) is a secreted glycoprotein highly expressed in tumours
from patients with advanced stage cancers, including prostate cancer (PCa). The exact
function of YKL40 is poorly understood, but it has been shown to play an important role in
promoting tumour angiogenesis and metastasis. The therapeutic value and biological
function of YKL40 are unknown in PCa. The objective of this study was to examine the
expression and function of YKL40 in PCa. Gene expression analysis demonstrated that YKL40
was highly expressed in metastatic PCa cells when compared with less invasive and normal
prostate epithelial cell lines. In addition, the expression was primarily limited to androgen
receptor-positive cell lines. Evaluation of YKL40 tissue expression in PCa patients showed a
progressive increase in patients with aggressive disease when compared with those with less
aggressive cancers and normal controls. Treatment of LNCaP and C4-2B cells with androgens
increased YKL40 expression, whereas treatment with an anti-androgen agent decreased the
gene expression of YKL40 in androgen-sensitive LNCaP cells. Furthermore, knockdown of
YKL40 significantly decreased invasion and migration of PCa cells, whereas overexpression
rendered them more invasive and migratory, which was commensurate with an
enhancement in the anchorage-independent growth of cells. To our knowledge, this study
characterises the role of YKL40 for the first time in PCa. Together, these results suggest that
YKL40 plays an important role in PCa progression and thus inhibition of YKL40 may be a
potential therapeutic strategy for the treatment of PCa.Key Words
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.0 UEndocrine-Related Cancer
(2014) 21, 723–737IntroductionEach year, more than 258 000 men will die of prostate
cancer (PCa), making PCa the second largest cause of
cancer-related mortality in males globally (Jemal et al.
2011, Siegel et al. 2012). While early-stage PCa can be
effectively treated by surgery or radiation therapy,metastatic PCa remains largely incurable. For locally
advanced and metastatic disease, androgen deprivation
therapy (ADT) is typically the first line of systemic therapy.
Although ADT is effective initially in most patients, the
cancer typically progresses within 12–36 months tosed under a Creative Commons
nported License.
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 724castration-resistant prostate cancer (CRPC; Pagliarulo et al.
2012). Cytotoxics such as docetaxel and cabazitaxel, new
androgen-targeted agents including abiraterone, enzalu-
tamide, ARN-509 and orteronel, as well as new radiation
agents such as RAD223 have provided significant clinical
advances (Ezzell et al. 2013, Sridhar et al. 2014). However,
despite these promising advances, CRPC remains a major
clinical challenge and there is a compelling need for more
effective therapies for patients withmetastatic disease. The
clinical development of new therapies is limited by the
availability of informative biomarkers to identify patients
who are likely to benefit from a particular type of therapy
and by the question whether these markers can act
simultaneously as a therapeutic target (Detchokul &
Frauman 2011, Citrin et al. 2013). YKL40 is one such
target that has shown promise in this area.
YKL40, also known as chitinase 3-like 1 (CHI3L1), is
a secretory glycoprotein and a member of the ‘family
18 chitolectins’. YKL40 is produced by inflammatory cells
and a variety of solid tumours, including breast, colon,
lung, prostate, ovary and kidney tumours and glioblas-
toma (Culig et al. 2004). Several studies have correlated
increased serum levels of YKL40 with the poor survival of
cancer patients, suggesting its potential as a prognostic
cancer biomarker (Jensen et al. 2003, Johansen et al. 2003,
2009, Bergmann et al. 2005). Evaluation of the serum
levels of YKL40 and a clinical biomarker, C-reactive
protein (CRP), demonstrated that elevated YKL40 levels
are associated with an increased risk of gastrointestinal
cancer, independent of CRP (Allin et al. 2012). In addition,
patients with metastatic breast cancer had significantly
higher serum concentration of YKL40 when compared
with the control group (Jensen et al. 2003, Yamac et al.
2008). Further evidence suggests that YKL40 is more than
a tumour biomarker and can function as a central player in
the growth, invasion, metastasis and treatment resistance
of cancer cells (Ku et al. 2011). Although the precise
function of YKL40 is not clear, it is presumed to play a
pivotal role in the proliferation and differentiation of
cancer cells, support cell survival by activating protein
kinase B (AKT) and inhibit apoptosis (Chen et al. 2011),
stimulate angiogenesis (Faibish et al. 2011, Francescone
et al. 2011), influence extracellular tissue remodelling
(Johansen 2006) and act as a growth factor for fibroblasts
(Recklies et al. 2002). YKL40 was also shown to promulgate
the growth of breast and glioblastoma tumours by
regulating angiogenesis, either independently or in
coordination with the vascular endothelial growth factor
axis (Shao et al. 2009, Francescone et al. 2011).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
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reported in patients with primary PCa compared with
those with benign prostate hyperplasia, suggesting that
YKL40 may influence the progression and aggressiveness
of PCa (Kucur et al. 2008). High serum YKL40 was also
associated with shorter overall survival and early death in
metastatic PCa patients undergoing hormonal therapy
(Brasso et al. 2006, Johansen et al. 2007). More recently,
investigations on the association of YKL40 with tumour
burden and metastatic stage of PCa suggested that the
elevated serum level of YKL40 may be a useful biomarker
of increased tumour burden and invasiveness in patients
with PCa and more informative than prostate-specific
antigen (PSA) for predicting tumour burden and metas-
tasis (Ozdemir et al. 2012). Despite these promising
clinical studies, much more remains to be understood
about the functional nature of YKL40. We therefore
hypothesised that YKL40 may be a potential therapeutic
target in PCa especially in metastatic CRPC and investi-
gated its regulatory functions.
In this study, we focused on evaluating the biological
role of YKL40 in PCa. We validated the expression of
YKL40 in PCa cell lines and investigated whether it is
regulated by androgens in PCa cells. We also determined
whether the tissue expression of YKL40 correlates with the
progression of clinical PCa. We further assessed the role
of YKL40 in promoting the migration and invasion of
PCa cells in addition to tumourigenicity.Materials and methods
Cell culture
All cell lines were maintained in phenol red-free RPMI-
1640 media supplemented with 5% foetal bovine serum
(FBS; Life Technologies Australia (LTA)), except for LAPC4
cells, which were cultured in phenol red-free IMDM (LTA)
supplemented with 10% FBS and 10K8 M dihydrotestos-
terone (DHT), and the human prostate epithelial cell line,
RWPE-1, which was cultured in keratinocyte serum-free
medium (LTA) supplemented with 50 mg/ml bovine
pituitary extract and 5 ng/ml epidermal growth factor.
LNCaP, 22RV1, PC3 and RWPE-1 cell lines were obtained
from the American Type Culture Collection (ATCC,
Rockville, MD, USA), whereas C42, C4-2B and LAPC4
cells were provided by Prof. Pamela Russell (Queensland
University of Technology, Australia). Cells were main-
tained in a humidified incubator (5% CO2 and 95% O2) at
37 8C. Authenticity of cell lines was confirmed by shortPublished by Bioscientifica Ltd.
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and cells were routinely tested for mycoplasma.Hormone treatments
To model the androgen-deprivation conditions in vitro,
cells were plated in FBS-containing medium and changed
to 5% charcoal-stripped serum (CSS) media for 48 h,
followed by treatment with optimised concentration of
androgens DHT (10 nM final) or R1881 (1 nM final),
and/or anti-androgen enzalutamide (10 mM final) for a
further 48 h unless otherwise stated. Cells were incubated
with enzalutamide 2 h before the addition of androgens.RNAi silencing and generation of stable cell lines
YKL40 knockdown was achieved by RNAi, using siRNA
specific to YKL40, as per the manufacturer’s recommen-
dations (Thermo Scientific Australia) for both LNCaP and
C4-2B cell lines. To achieve the best knockdown, four
different siRNAs were screened to select for the one
showing the highest (R70%) gene silencing efficiency
48 h after transfection with lipofectamine (LTA). YKL40
overexpression was achieved using the Precision LentiORF
(pLOC) lentiviral vector system (Thermo Scientific
Scoresby, Victoria, Australia). Lentiviral production was
performed by co-transfection of pLOC vectors into 293T
cells in the presence of pCMV-dR8.2 and pCMV-VSV-G
packaging plasmids (Addgene, Cambridge, MA, USA).
Cells were transduced with viral supernatants containing
protamine sulphate (6 mg/ml) overnight and selected with
the medium containing 10 mg/ml blasticidin.RT quantitative PCR
Total RNA was extracted using the RNeasy Mini System
(Qiagen, Chadstone, Victoria, Australia) with on-column
DNase treatment to remove contaminating DNA as per the
manufacturer’s guidelines (Qiagen). Samples were quanti-
fied by measuring the absorbance at 260 nm (Nanodrop,
Wilmington,DE,USA). cDNAprepared from total RNA (first
strand cDNA synthesis kit, LTA) was used to assess the
expression of target genes using a SYBR Green Kit (LTA) in
the 7900HT Fast Real Time PCR System (Applied Biosys-
tems). The primers used were as follows: YKL40 forward (f),
50-cccaacctgaagactctcttg-30 and YKL40 reverse (r), 50-ccaaga-
tagcctccaacacc-30;AR (f), 50-ctggacacgacaacaaccag-30 andAR
(r), 5 0-cagatcaggggcgaagtaga-3 0 and RPL32 (f), 5 0-gcaa-
caaatcttactgtgccga-3 0 and RPL32 (r), 5 0-gcattggggttggt-
gactct-30. Samples were normalised to the housekeepinghttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
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Printed in Great BritaingeneRPL32and thento thecorrespondingcontrols. Relative
mRNAexpressionwasanalysedby the2KDDCtmethod(Livak
& Schmittgen 2001).Immunoblotting
The protein expression of different genes was estimated by
western blotting-based analysis. Cell culture medium was
replaced with serum-free medium for 24 h and the
supernatant was collected. Protein was concentrated from
the cell culture supernatant using Amicon Ultra-2 centri-
fugal filter unit with ultracel-10 membrane (Merck Milli-
pore, Kilsyth, Victoria, Australia). Whole cell lysates were
prepared under non-denaturing conditions by treating cells
with cell lysis buffer (Cell Signaling Technology (CST),
Danvers, MA, USA) containing protease inhibitor cocktail
(Roche, CastleHill, New SouthWales, Australia). All protein
samples were quantified by the BCA assay kit (Pierce,
Rockford, IL, USA). Briefly, an equal amount of protein was
resolved by SDS/PAGE and transferred onto the nitrocellu-
losemembrane. Blots were probed with primary antibodies,
which are as follows: anti-CHI3L1 (1:500, R&D Systems,
Minneapolis, MN, USA), anti-AR (1:1000, CST), b-tubulin
(1:10 000, Sigma–Aldrich) and b-actin (1:10 000, CST). ECL-
compatible secondary antibodies, anti-goat HRP (1:10 000,
SantaCruzDallas,TX,USA), anti-mouseHRPandanti-rabbit
HRP (1:10 000, GE Healthcare, Silverwater, New South
Wales, Australia), were used. b-actin and b-tubulin were
used as loading controls. Additionally, TGX stain-free gels
(Bio-Rad, Gladesville, New South Wales), which show total
protein content after SDS/PAGE,were used to validate equal
protein loading. Proteins were visualised using an ECL Kit
(Merck Millipore) on Bio-Rad’s ChemiDoc XRSC system
with the image lab software. Densitometry analysis was
performed on Bio-Rad’s Image Lab Software (version 4.1).Evaluation of YKL40 expression in PCa patients
The human ‘Tissue Scan quantitative PCR (qPCR) array’
(HPRT502, HPRT503; Origene, Rockville, MD, USA) was
used for determining the mRNA expression of YKL40 in
clinical samples of matched normal prostate and PCa
tissues. The cancer specimens included various tumour–
lymph node–metastasis (TNM) stages and Gleason grades
of PCa. Tissue cDNAs of each array were synthesised by the
manufacturer from high-quality total RNAs of pathologist-
verified PCa tissues, normalised and validated with b-actin
and provided with clinicopathological information,
including age, sex, tumour stage, pTNM stage, etc.
(Table 1 and Supplementary Table 1, see section onPublished by Bioscientifica Ltd.
Table 1 Summary overview of patient cohorts used in this study
Clinical characteristics
Relative
YKL40
expression
(meanGS.D.)
P value
(normal vs
tumour –
stages and
grades)
Patient’s age (years)
Age range at diagnosis or
at tissue excision
46–87
Mean age 62
Percentage of cancer (%) 40–95
Cells in tumour tissue
Mean (%) 76
Number of control samples
Normal adjacent 17 1.25G0.8
Number of tumour
samples
Stage T2 40 5.08G3.23 0.0483
Stage T3 30 7.89G2.23 0.0001
Stage T4 4 12.14G2.9 0.0035
Gleason 5 and 6 10 2.36G2.00 0.0631
Gleason 7 44 4.51G2.20 0.0073
Gleason 8 13 5.49G2.07 0.0028
Gleason 9 8 7.52G1.97 0.0035
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RT-qPCR was performed as explained above. Gene
expression was normalised to the housekeeping gene
b-actin (forward- and reverse-) supplied with the array kit.Cell migration assays
Monolayer wound-healing cell migration assays were
performed using a real-time cell imaging system (Incucyte,
Essen Bioscience (EB), Ann Arbor, MI, USA) in which cells
are imaged inside a standard incubator under optimal
physiological conditions for the entire duration of the
experiment. Briefly, 96-well image lock plates (EB) were
coated overnight with poly-ornithine (40 ml, Sigma) for
improving cell adherence and LNCaP andC4-2B cells (2.5!
104) were plated the following day. Cells were grown to
confluence (usually 24 h) and treated with an optimised
dose of anti-proliferation agent, mitomycin C (20 mM,
Sigma), for 2 h before scratching to neutralise the effect of
proliferation on cell migration. Scratches were made with a
96-pin wound maker (EB) and the wells were washed with
PBS to remove any debris before replenishment with 100 ml
media containing 5% CSS. For YKL40 siRNA experiments,
1.5!104 cells were plated overnight to achieve 50–60%
confluency followed by incubation with an optimised
concentration of either siRNA or scrambled non-specific
siRNA controls in 100 ml serum-free media for 4 h, and then
5 ml CSS was added on top (i.e. 5% CSS/well). Cells were
allowed to form a confluent monolayer after transfectionhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
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Printed in Great Britain(up to 72 h) and then scratched and imaged. The wound
closure was quantified by an integrated metric: relative
wound density (RWD). This metric relies on measuring the
spatial cell density in the wound area relative to the spatial
cell density outside of the wound area at every time point,
thus RWD is self-normalising for the changes in wound
density, which may occur outside the wound due to cell
proliferation and/or pharmacological effects (EB). Images
captured at 2 h intervals were collated into video files using
the Incucyte imaging software. All samples were evaluated
in six replicates in four independent experiments.Invasion assays
LNCaP and C4-2B cells (2.5!104) were grown on the image
lock plates coated overnight with Matrigel (BD Biosciences,
San Jose, CA, USA; diluted to 100 mg/ml in serum-free
media) and a wound was induced with the woundmaker as
explained above, following which another layer of Matrigel
(1 mg/ml) was added on top. Cells were prepared as
explained in the preceding section. Time-lapse images of
cells penetrating through Matrigel were acquired and data
weremonitored and quantified using the Incucyte Software
as described above. All samples were evaluated in six
replicates in three independent experiments.Anchorage-independent growth assays
Anchorage-independent growth was evaluated by the soft
agar colony count assay in three different experiments.Cells
were seeded (5!103 cells/well) in triplicate in six-well plates.
Colonies (R20 cells) were counted after 14 days using a
dissecting microscope. Briefly, a base layer of agar was
prepared bymixing equal volumes of 1.2% agarose at 37 8C,
andpre-warmed2!DMEMwith10%FBSpouredontoa six-
well plate (2 ml/well) and allowed to polymerise overnight
in the incubator. The top agar layer was made by mixing
equal volumes of warm 0.6% agarose and 2! DMEM with
10% FBS-containing 5000 cells from each experimental cell
line (2 ml/well). Top agar containing cells was poured onto
the base agar and the plateswere incubated at 37 8C/5%CO2
andmedia (0.5 ml) were replenished every 3 days. Colonies
were counted bymanually drawing squares underneath the
plate for visible demarcation and the colony count was
plotted from the average of 16 different fields per well.Statistical analysis
Two-tailed Student’s t-test with the Mann–Whitney U test
and one-way ANOVA with Tukey’s multiple comparisonPublished by Bioscientifica Ltd.
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La Jolla, CA, USA). The P value of %0.05 was considered
significant. Results are representative of at least three
independent experiments with triplicate samples, unless
stated otherwise.B
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Figure 1
Expression of YKL40 in PCa cell lines: (A) RT-qPCR analysis showing the gene
expression of YKL40 in PCa cell lines. All samples were normalised to the
corresponding housekeeping gene, RPL32, and then normalised relative to
LNCaP. All samples were evaluated in triplicate and the average values of
the three independent experiments are expressed as meanGS.E.M.
(B) Secreted levels of YKL40 protein (40 kDa) were evaluated by culturing
cells in the serum-free medium for 24 h, following which protein was
concentrated from the supernatant and equal amounts were resolved by
immunoblotting. TGX stain-free gels were used to represent total protein
loading from cell culture supernatants. Additionally, b-actin (45 kDa) was
used as an internal control. Data represent the average of threeResults
Expression of YKL40 in PCa cell lines
We first evaluated the gene expression of YKL40 in a panel
of PCa cell lines. We found that C42 and C4-2B cells, more
invasive derivatives of LNCaP cell line, expressed signi-
ficantly higher levels of YKL40 mRNA, when compared
with LNCaP cells. Other androgen receptor (AR)-positive
cell lines, 22RV1 and LAPC4, AR-negative (ARKve) PC3
cells and the normal prostate epithelial cell line, RWPE-1,
did not show any significant difference in the expression
levels of YKL40 mRNA, in comparison to LNCaP cells
(Fig. 1A). In agreement with the gene expression findings,
the secreted protein levels of YKL40 in cell culture
supernatants were highest in C4-2B cells, followed by
C42 and LNCaP, and lowest in LAPC4, PC3 and RWPE-1
cells (Fig. 1B). Furthermore, we assessed the intracellular
protein expression of YKL40 in whole cell lysates of cell
lines and observed that the results correlated with the
mRNA expression levels (Fig. 1C). Although 22RV1 cells
displayed relatively high levels of secreted YKL40 (Fig. 1B),
the intracellular protein expression correlated with mRNA
expression (Fig. 1C). These results taken together suggest
that YKL40 expression increased with progression to CRPC
phenotype in ARCve, hormonally responsive cell lines.
On the basis of these results, we decided to use LNCaP
and C4-2B cells for subsequent studies, as they represent
the progression of PCa disease from androgen-dependent
disease (LNCaP) to CRPC bone metastatic disease (C4-2B),
while remaining hormonally responsive (Thalmann et al.
1994, 2000).
independent experiments. (C) Intracellular expression of YKL40 was
determined by western blotting in PCa cell lines with b-actin serving as the
internal control. Data represent the average of three independent
experiments. Densitometry values for YKL40, normalised to b-actin and
presented relative to LNCaP (first lane; set as onefold), are included below
the lanes. *P!0.05, **P!0.01, ***P!0.001 and #P!0.05.Androgen treatment induces the expression of YKL40
As the expression of YKL40 correlated with the progression
to castration resistance in ARCve PCa cells, we then
determined whether YKL40 was regulated by androgens.
This was achieved by evaluating the gene expression of
YKL40 in the presence and absence of androgens (DHT and
R1881) and the anti-androgen agent (enzalutamide) using
RT-qPCR. We found that YKL40 mRNA was significantly
elevated in LNCaP cells in response to both 10 nM DHT
(4.30-fold, P!0.001) and 1 nMR1881 (4.55-fold, P!0.001).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great BritainThis response was blunted in C4-2B cells, which showed
small but significant responses to both DHT (1.59-fold,
P!0.05) and R1881 (1.65-fold, P!0.05) (Fig. 2A). Further-
more, the androgen-induced increase in YKL40mRNA was
significantly abrogated upon treatment with 10 mM enza-
lutamide in LNCaP cells, whereas C4-2B cells did not show
any significant reduction (Fig. 2A). The weak androgenPublished by Bioscientifica Ltd.
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Figure 2
Androgen receptor-mediated regulation of YKL40 expression in LNCaP
and C4-2B cell lines: (A) RT-qPCR analysis showing the effect of androgens
(DHT and R1881) and anti-androgen enzalutamide (Enz) on YKL40 gene
expression. All samples were normalised to the corresponding house-
keeping gene, RPL32, and then normalised relative to the vehicle (ethanol)
control (meanGS.E.M., nZ3 for three separate experiments). (B) Secreted
levels of YKL40 after treatment with androgens were determined by
western blotting. TGX stain-free gel was used as a loading control.
Data represent the average of three independent experiments. RT-qPCR
and immunoblotting showing the efficacy of AR knockdown (siAR) at the
gene (C, meanGS.E.M., nZ3) and protein (D, nZ3) levels. (E) Effect of AR
silencing (siAR) on YKL40 gene expression as evaluated by RT-qPCR
(meanGS.E.M., nZ3). (F) Representative western blot showing the effect of
AR protein knockdown on YKL40 protein expression. b-tubulin (50 kDa)
served as an internal control (nZ3). Densitometry values for specific
proteins, normalised to loading controls and presented relative to vehicle
controls (set as onefold), are included below the lanes. *P!0.05, **P!0.01
and ***P!0.001.
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baseline expression of androgen-activated genes in these
cells. The upregulation of YKL40 mRNA with androgen
treatment was accompanied by a commensurate increase in
secreted YKL40 protein levels (Fig. 2B). When compared
with the vehicle control, YKL40 protein was significantly
upregulated in both DHT- and R1881-treated LNCaP cells
(P!0.05). Similarly, C4-2B cells displayed a significant
upregulation of YKL40 protein levels following treatment
with either DHT or R1881 (P!0.05; Fig. 2B).
To further examine whether androgen induction of
YKL40 is mediated by AR, AR-targeted siRNA was used to
suppress AR gene and protein expression (Fig. 2C and D).
We found that the mRNA expression of YKL40 washttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great Britainsignificantly downregulated after AR knockdown in both
LNCaP and C4-2B cell lines (Fig. 2E, P!0.05). However,
while we observed a reduction in the YKL40 protein
expression after AR knockdown, this decrease was not
significant (Fig. 2F). This finding indicates that although
YKL40 is responsive to androgens, there may be other
mechanisms contributing to YKL40 production. This
seems to be especially true for C4-2B cells, which, despite
their positive AR status, also show castration resistance.Expression of YKL40 in PCa patients
After elucidating the YKL40 expression patterns in the
in vitro model system, we examined the expression levelsPublished by Bioscientifica Ltd.
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levels of YKL40 have been reported in PCa patients, no
data are available regarding the tissue specific expression
of YKL40 in PCa. To investigate this, we utilised
commercial cDNA arrays encompassing various TNM
stages and Gleason grades of the disease (Table 1 and
Supplementary Table 1). When compared with the
matched normal controls, significantly higher expression
of YKL40 was found in TNM stage II (P!0.01), stage III
(P!0.0001) and stage IV patients (P!0.01) (Fig. 3A).
Differences between the stages were also observed as TNM
stage III (P!0.001) and stage IV (P!0.05) patients had
significantly higher levels of YKL40 compared with TNM
stage II patients (Fig. 3A). We then categorised these
patients on the basis of Gleason grades and found that
Gleason grade 7, 8 and 9 tumour tissues had significantly1000A B
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Figure 3
YKL40 gene expression in matched normal and PCa tissues: (A) gene
expression of YKL40 was determined in PCa patients representing
progressive TNM stages when compared with the matched normal prostate
tissue using RT-qPCR. Data are expressed as median values of three
independent experiments. (B) RT-qPCR analysis showing YKL40 mRNA
expression in different Gleason grades of PCa when compared with the
control tissue. Data represent the median values of three independent
experiments. (C) Expression of YKL40 in primary and metastatic PCa cells
when compared with the corresponding normal samples in microarray data
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Printed in Great Britainhigher levels of YKL40 when compared with the normal
controls (Fig. 3B). However, we did not find any significant
differences among the Gleason grades (Fig. 3B). In silico
analysis of YKL40 mRNA expression using publicly
available gene expression data (Gene Expression Omnibus
datasets (GDS), http://www.ncbi.nlm.nih.gov/gds) found
YKL40 gene expression to be significantly increased in
patients with metastatic PCa when compared with
primary PCa and normal prostate tissue (Fig. 3C,
GDS2545; Chandran et al. 2007). Furthermore, a signi-
ficant difference between primary PCa and normal tissue
was also measured (Fig. 3C, GDS2545; Chandran et al.
2007). We also extracted information from the publicly
accessible ‘The Cancer Genome Atlas (TCGA)’ RNA-
sequencing dataset and evaluated the expression of
YKL40 in normal adjacent prostate tissue vs prostateC
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 730tumour tissues. TCGA results showed that YKL40 mRNA
is significantly increased in PCa tumour tissue when
compared with the non-cancerous tissue (Fig. 3D).
Additional analysis revealed higher expression of YKL40
in patients with biochemically recurrent (three consecu-
tive increases in the serum level of PSA after radical
prostatectomy) PCa disease when compared with those
with non-recurrent disease (Fig. 3E, GDS4109; Sun &
Goodison 2009), which also corroborates the trends
observed at the protein level in a previous study (Johansen
et al. 2007). Our findings, coupled with previous reports,
firmly highlight the potential role of YKL40 in the PCa
disease progression.C
YKL40
β-actin
YKL40
C4-2B LNCaP C4-2B LNCaP
β-actin
1.00
RFP control YKL.OE
1.000.36## 0.39##
Figure 4
Knockdown and overexpression of YKL40 in PCa cells: (A) the optimisation
of YKL40 knockdown to select for the siRNA showing the maximum
knockdown as determined by RT-qPCR (meanGS.E.M., nZ3). *P!0.05,
**P!0.01 and ***P!0.001. (B) The confirmation of YKL40 knockdown at
the translational level by western blotting (nZ3). ##P!0.01 (vs scrambled
control). (C) The representative western blot of stable overexpression of
YKL40 in control (RFP) and YKL40-overexpressing (YKL.OE) cells.Characterising the functional role of YKL40 in PCa cells:
determination of migration, invasion and anchorage
independence
Previous studies have supported a functional role for
YKL40 in promoting metastasis, invasion and angiogen-
esis in multiple tumour types. Results from our analysis of
the LNCaP–C4-2B progression model and the in silico gene
expression of clinical specimens indicate that YKL40 is
consistently upregulated in advanced PCa. We therefore
sought to investigate whether YKL40 plays a functional
role in biological phenotypes relevant to the invasion and
metastasis of PCa cells. To achieve this, we first tested four
individual siRNA sequences specific to YKL40 (Y110, Y210,
Y310 and Y410) to identify the optimal siRNA for
suppression of endogenous YKL40 expression in LNCaP
and C4-2B cell lines (Fig. 4A). The siRNA clone Y110
(subsequently referred to as siYKL) was found to efficiently
suppress YKL40 mRNA (Fig. 4A) and protein expression
(Fig. 4B) in both cell lines. LNCaP and C4-2B cell lines
overexpressing YKL40 (YKL.OE) were generated via the
stable expression of the YKL40 open reading frame using
the pLOC lentiviral vector. Cell lines stably expressing red
fluorescent protein (RFP) were also generated as controls.
The overexpression of YKL40 in LNCaP and C4-2B cells
was confirmed by western blotting (Fig. 4C).YKL40 increases the migratory potential of PCa cells
YKL40 has previously been reported to induce migration
of endothelial (Malinda et al. 1999) and glioblastoma cells
(Ku et al. 2011) in vitro. As a higher rate of cell migration is
a hallmark of aggressive cancers, we postulated that YKL40
might induce the migration of PCa cells. To investigate
this possibility, we monitored the effect of YKL40 on
the migratory potential of PCa cells using monolayerhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great Britainwound-healing assays. We found that overexpression of
YKL40 in LNCaP cells (YKL.OE) significantly enhanced
their ability to migrate into the wounded area (P!0.001)
(Fig. 5A and C; Supplementary Movies 1 and 2, see section
on supplementary data given at the end of this article). By
contrast, the suppression of endogenous YKL40 expression
using siYKL led to a small but significant reduction in the
LNCaP wound closure (P!0.05; Fig. 5B and D; Supple-
mentary Movies 3 and 4). In C4-2B cells, the effect of
YKL40 knockdown on the rate of migration was much
more pronounced compared with that observed in LNCaP
cells and resulted in a significant reduction in the
percentage of migrating cells (P!0.001; Fig. 6A and C;
Supplementary Movies 5 and 6). Confirming the resultsPublished by Bioscientifica Ltd.
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Figure 5
YKL40-mediated cell migration in LNCaP cells: (A) stably transduced LNCaP
cells were grown to confluence and a wound was made using a 96-well
wound maker and images were recorded over 2 days. Representative
images are shown for RFP control cells at time points – 0 h (RFP–0 h) and
48 h (RFP–48 h). Similarly, YKL40-overexpressing (YKL.OE) LNCaP cells were
scratched and real-time images were captured over 48 h. Representative
images are shown at 0 h (YKL.OE–0 h) and 48 h (YKL.OE–48 h).
(B) Scrambled control and YKL40-silenced cells (siYKL) were scratched and
representative images are shown at time points – 0 h (scrambled–0 h,
siYKL–0 h) and 48 h (scrambled–48 h, siYKL–48 h). Red dotted lines outline
the extent of migration. The percentage of cells that migrated through the
wounded area was plotted as relative wound density in RFP control vs
YKL.OE cells (C) and scrambled control vs siYKL cells (D). Data represent
meanGS.E.M., nZ4. Photomicrographs were taken at 10! magnification.
*P!0.05 and ***P!0.001. A full colour version of this figure is available at
http://dx.doi.org/10.1530/ERC-14-0267.
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 731observed in LNCaP cells, the overexpression of YKL40 in
C4-2B cells (YKL.OE) led to a significant increase in C4-2B
cell migration (P!0.05) (Fig. 6B and D; Supplementary
Movies 7 and 8).YKL40 increases the invasive potential of PCa cells
Given that YKL40 is known to drive tumour cell
invasiveness (Ku et al. 2011, Singh et al. 2011), we
performed invasion assays to determine the role of
YKL40 in the invasion of cells throughMatrigel. In concert
with the cell migration data, we found that YKL40
overexpressing LNCaP cells displayed significantly
increased invasion through Matrigel when compared
with the RFP control cells (P!0.001; Fig. 7A and C;
Supplementary Movies 9 and 10, see section on supple-
mentary data given at the end of this article). By contrast,
the suppression of YKL40 expression in LNCaP cellshttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great Britain(siYKL) led to reduction in the number of invading cells
(P!0.05) (Fig. 7B and D; Supplementary Movies 11 and
12). Similarly, the suppression of YKL40 expression in
C4-2B cells significantly reduced cell invasion (P!0.001;
Fig. 8A and C; Supplementary Movies 13 and 14), while
overexpression of YKL40 did not yield a significant change
(Fig. 8B and D; Supplementary Movies 15 and 16).YKL40 promotes clonal growth in vitro
As the ability of cells to grow in the absence of adhesion is
a feature of malignant transformation, we investigated the
effect of YKL40 on colony formation in soft agar. In LNCaP
cells, YKL40 overexpression (YKL.OE) produced a signi-
ficantly higher number of colonies when compared with
the RFP control cells (P!0.001; Fig. 9A and B), whereas
siYKL–LNCaP cells did not show any significant reduction
(Fig. 9C). However, YKL40 silenced C4-2B cells showed aPublished by Bioscientifica Ltd.
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Figure 6
YKL40-mediated cell migration in C4-2B cells: (A) stably transduced cells
were grown to confluence and a wound was made by the 96-well wound
maker and images recorded over two days using time-lapse microscopy.
Representative images are shown for RFP control cells at time points – 0 h
(RFP–0 h) and 48 h (RFP–48 h). Similarly, YKL40-overexpressing (YKL.OE)
C4-2B cells were scratched and real-time images were captured over 48 h.
Representative images are shown at 0 h (YKL.OE–0 h) and 48 h
(YKL.OE–48 h). (B) Scrambled control and YKL40-silenced cells (siYKL) were
scratched and representative images are shown at time points – 0 h
(scrambled–0 h, siYKL–0 h) and 48 h (scrambled–48 h, siYKL–48 h).
Red dotted lines outline the extent of migration. The percentage of cells
that migrated through the wounded area was plotted as relative wound
density in RFP control vs YKL.OE cells (C) and scrambled control vs siYKL
cells (D). Data represent meanGS.E.M., nZ4. Photomicrographs were taken
at 10! magnification. *P!0.05 and ***P!0.001. A full colour version of
this figure is available at http://dx.doi.org/10.1530/ERC-14-0267.
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 732significant decrease in the number of colonies when
compared with the scrambled control (P!0.01; Fig. 9C
and D), while YKL.OE C4-2B cells did show a slight, but
insignificant, increase in the colony numbers (Fig. 9A).
This result indicates that as C4-2B cells have a higher basal
YKL40 expression, knockdown of YKL40 resulted in the
marked decrease in colony numbers, while overexpression
of YKL40 in LNCaP cells enhanced the colony formation.Discussion
To our knowledge, this study provides persuasive evidence
for a functional role for YKL40 in PCa for the first time.
Although the credentials of YKL40 as a prognostic
biomarker have been investigated in PCa, the role it plays
in PCapathobiology has not beenpreviously explored.Our
results show that YKL40 expression increased with
progression to a CRPC phenotype in ARCve, androgen-
responsive cell lines. In addition, the tissue expression ofhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great BritainYKL40 correlated with the aggressiveness and progression
of clinical PCa. We also show that YKL40 affects cell
invasion, migration and anchorage-independent growth
of PCa cells in vitro. These findings have provided in vitro
biological evidence as to how the elevated serum levels of
YKL40 reported in PCa patients may contribute to the
tumour progression and metastasis of PCa.
YKL40 has been reported as a promising biomarker in
several cancer types and also in a number of inflammatory
disorders (Johansen et al. 2006). It has been reported that
16–74% of patients had elevated levels of serum YKL40 at
the time of first cancer diagnosis; however, the percentage
increased from 39–83% at diagnosis in patients with
metastatic cancer (Johansen et al. 2006). Despite the
prognostic elucidation of YKL40 in a broad spectrum of
cancers, the exact function of YKL40 is poorly understood.
Accumulating evidence suggests that YKL40 ismore than a
prognostic biomarker and has the capacity to influence a
wide range of cellular processes,most notably angiogenesisPublished by Bioscientifica Ltd.
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Figure 7
YKL40-mediated cell invasion in LNCaP cells: (A) cells were layered onto
Matrigel-coated plates and the wound was made using the wound maker
followed by adding another layer of Matrigel on top. Representative
images are shown at 0 h (RFP, YKL.OE–0 h) and 48 h (RFP, YKL.OE–48 h).
(B) Scrambled control and YKL40-silenced cells (siYKL) were scratched and
representative images are shown at time points – 0 h (scrambled–0 h,
siYKL–0 h) and 48 h (scrambled–48 h, siYKL–48 h). Red dotted lines outline
the extent of invasion. The percentage of cells that invaded through the
wounded area was plotted as relative wound density in RFP control vs
YKL.OE cells (C) and scrambled control vs siYKL cells (D). Data are expressed
as meanGS.E.M., nZ3. Photomicrographs were taken at 10! magni-
fication. *P!0.05 and ***P!0.001. A full colour version of this figure is
available at http://dx.doi.org/10.1530/ERC-14-0267.
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 733and metastasis. In fact, emerging interest in the focused
targeting of YKL40 led to the development of a YKL40-
neutralising antibody, which abrogated tumour angiogen-
esis and progression of the glioblastoma cells in vitro and
in vivo using animal models (Faibish et al. 2011).
As the expression of YKL40 by PCa cells is unclear, we
first analysed the expression pattern of YKL40 in PCa cell
lines and tissues. We discovered that the expression of
YKL40 was significantly increased in ARCve PCa cell lines
as they progressed towards a castrate-resistant and
metastatic phenotype when compared with ARKve PCa
and normal prostate epithelial cells, suggesting that
YKL40 may be regulated in an androgen-dependent
manner in the PCa cell setting. Indeed, we confirmed
that YKL40 was upregulated in both LNCaP and LNCaP-
derived C4-2B cell line in response to androgens (DHT and
R1881), whereas this androgen-induced YKL40 expression
was inhibited via co-treatment of androgen-sensitive
LNCaP cells with the anti-androgen, enzalutamide, an
effect not observed in the castration-resistant C4-2B cell
line. We then monitored the direct effect of AR silencinghttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great Britainon YKL40 expression. Although the mRNA expression of
YKL40 decreased significantly after AR knockdown, we did
not observe the similar effect at the protein level. This
result suggests that the expression of YKL40 is likely to be
regulated by other pathways outside of AR at the
translational level. Indeed, YKL40 is known to be
regulated by PI3K/AKT (Recklies et al. 2002) and JNK/ERK
(Ling & Recklies 2004) and these pathways play a crucial
role in prostate carcinogenesis (Rodriguez-Berriguete et al.
2012, Bitting & Armstrong 2013). The bidirectional
crosstalk between the AR and AKT pathways has been
shown to fuel the growth of castration-resistant PCa cells
(Wang et al. 2007, Kaarbo et al. 2010, Chandarlapaty et al.
2011, Mulholland et al. 2011) and phospho-ERK has been
identified as a potential link between the PI3K/AKT
pathway and the AR axis (Thomas et al. 2013). Thus, it is
possible that YKL40 is similarly regulated in PCa cells;
however, this concept requires further investigation.
Our current study also elucidated the expression
profile of YKL40 in PCa tissue specimens. We have
demonstrated that levels of YKL40 mRNA increased inPublished by Bioscientifica Ltd.
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Figure 8
YKL40-mediated cell invasion in C4-2B cells: (A) C4-2B cells were layered
onto Matrigel-coated plates and the wound was made using the wound
maker followed by adding another layer of Matrigel on top. Representa-
tive images are shown at 0 h (RFP, YKL.OE–0 h) and 48 h (RFP, YKL.OE–48 h).
(B) Scrambled control and YKL40-silenced cells (siYKL) were scratched and
representative images are shown at time points – 0 h (scrambled–0 h,
siYKL–0 h) and 48 h (scrambled–48 h, siYKL–48 h). Red dotted lines outline
the extent of invasion. The percentage of cells that invaded through the
wounded area was plotted as relative wound density in RFP control vs
YKL.OE cells (C) and scrambled control vs siYKL cells (D). Data are expressed
as meanGS.E.M., nZ3. Photomicrographs were taken at 10! magni-
fication. ***P!0.001. A full colour version of this figure is available at
http://dx.doi.org/10.1530/ERC-14-0267.E
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 734higher TNM stages and Gleason grades of PCa when
compared with the matched normal prostate tissue. This
result is consistent with the previous clinical findings that
serum levels of YKL40 correlate with the progression of
PCa (Johansen et al. 2007, Kucur et al. 2008, Ozdemir et al.
2012). However, we did not find any significant differences
in YKL40 levels among the Gleason grades, which supports
the findings of Ozdemir et al. (2012) in PCa serum samples.
One reason to explain the lack of association with Gleason
grade may be the relatively small number of samples
screened in our study, in addition to the fact that YKL40
may be selectively upregulated in the metastatic group of
patients in such cases. We have also analysed YKL40 gene
expression in the publicly available microarray and RNA-
sequencing datasets, which corroborate our findings that
YKL40 gene expression increases progressively with
advanced stages of PCa. Thus, our study along with
other studies has shown that high expression of YKL40
in PCa tissues is associated with a more aggressive
phenotype with a high metastatic potential.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great BritainCell migration and invasion together is a fundamental
process underlying cellular processes, such as angiogen-
esis, embryonic development, immune response, metas-
tasis and invasion of cancer cells. Based on the initial
characterisation of YKL40 in cancer cell lines and PCa
tissues, we investigated the role of YKL40 in processes
underlying metastasis. We revealed that knockdown of
YKL40 in the bone metastatic C4-2B cells decreased both
migration and invasion, whereas overexpression in less
aggressive LNCaP cells rendered themmore migratory and
invasive. Our data are in accordance with multiple studies
implicating the role of YKL40 in promoting tumour cell
mobility and invasiveness accompanied with an increased
metastatic potential (Johansen et al. 2006). Although we
did not explore the mechanisms involved in this action
of YKL40, others have proposed that YKL40 acts through
the transcription factors, NFIX3 and STAT3, and through
regulation of MMP2 to promote glioma cell invasion and
migration (Ku et al. 2011, Singh et al. 2011). Interestingly,
Stat3 has been shown to promote the metastaticPublished by Bioscientifica Ltd.
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Figure 9
Effect of YKL40 on anchorage-independent growth: anchorage-indepen-
dent growth of LNCaP and C4-2B cells was assessed by soft agar colony count
assay. (A) YKL40-overexpressing (YKL.OE) and RFP control cells were plated in
soft agar and the colony count was performed after 14 days.
(B) Representative images of LNCaP–RFP vs YKL.OE cells, magnification 20!.
(C) YKL40-silenced and scrambled control cells were seeded in soft agar and
the colonies were counted after 2 weeks. (D) Representative photomicro-
graphs of C4-2B cellsGYKL40 knockdown, magnification 20!. Data are
expressed as meanGS.E.M., nZ3. **P!0.01 and ***P!0.001. A full colour
version of this figure is available at http://dx.doi.org/10.1530/ERC-14-0267.
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Research V Jeet et al. Role of YKL40 in prostate cancer 21 :5 735progression of human PCa cells in vitro and in vivo
(Abdulghani et al. 2008, Gu et al. 2010) and inhibition of
Stat3 suppressed PCa cell growth and invasion (Sun et al.
2012). MMP2 also induces PCa cell migration upon
activation by androgens via PI3K-dependent androgen
receptor transactivation (Liao et al. 2003). Moreover, a
recent study has shown that YKL40 stimulates the
migration of colon cancer cells through the secretion of
chemokines, IL8 and MCP1, through the MAPK signalling
pathway (Kawada et al. 2012). In addition, YKL40
displayed the ability to enhance tumour metastasis via
regulating the activation of pro-inflammatory cytokines in
the animal models of metastatic breast cancer (Libreros
et al. 2012). Together, these studies provide valuable
information about the possible mechanisms of YKL40-
mediated migration and invasion.
The ability of cancer cells to grow in the absence of
adhesion to basement membrane, termed anchorage
independence, correlates closely with tumourigenicity in
animal models (Freedman & Shin 1974, Jiang & Liao
2004). Anchorage independence allows tumour cells to
proliferate and invade adjacent tissues and to disseminate
through the body, thus giving rise to metastasis. In ahttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0267
q 2014 The authors
Printed in Great Britainxenograft mouse model using human glioblastoma cell
lines, YKL40 was shown to positively regulate tumour-
igenesis and metastasis (Francescone et al. 2011). Clono-
genic growth assays also elucidated the ability of YKL40 to
encourage anchorage-independent growth during inva-
sion by inhibiting anoikis-related apoptotic pathways of
glioma cells (Ku et al. 2011). Similarly, our results indicate
that YKL40 suppression inhibits, and YKL40 overexpres-
sion increases, the anchorage-independent growth of
PCa cells. Although molecular mechanisms responsible
for this behaviour of YKL40 in PCa cells remain yet to be
investigated, our preliminary results highlight the
potential role of YKL40 in promoting tumourigenicity.
To conclude, our study characterises the role of YKL40
for the first time in PCa and provides valuable insights into
its function in PCa cells. Collectively our results suggest
that the development of a targeted agent against YKL40
may provide a novel strategy to inhibit the progression of
metastatic PCa. Should such an agent reach clinical trials,
measurement of serum levels of YKL40 may provide an
opportunity to stratify patients, given the reliable detec-
tion of YKL40 in serum and thus optimising the efficacy of
YKL40-targeted approaches.Published by Bioscientifica Ltd.
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